Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

A novel quantification-dr… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease

Artikel i vetenskaplig tidskrift
Författare Tobias Skillbäck
Niklas Mattsson
Karl Hansson
Ekaterina Mirgorodskaya
Rahil Dahlén
W. van der Flier
P. Scheltens
F. Duits
O. Hansson
C. Teunissen
Kaj Blennow
Henrik Zetterberg
Johan Gobom
Publicerad i Scientific Reports
Volym 7
ISSN 2045-2322
Publiceringsår 2017
Publicerad vid Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi
Core Facilities, Proteomics
Språk en
Länkar doi.org/10.1038/s41598-017-13831-0
Ämnesord cerebrospinal-fluid biomarkers, tandem mass-spectra, tyrosine-phosphatase beta/zeta, mild cognitive impairment, affin, regulatory peptide, molecule hb-gam, diagnostic-criteria, chondroitin, sulfate, growth, receptor
Ämneskategorier Neurovetenskaper

Sammanfattning

We present a new, quantification-driven proteomic approach to identifying biomarkers. In contrast to the identification-driven approach, limited in scope to peptides that are identified by database searching in the first step, all MS data are considered to select biomarker candidates. The endopeptidome of cerebrospinal fluid from 40 Alzheimer's disease (AD) patients, 40 subjects with mild cognitive impairment, and 40 controls with subjective cognitive decline was analyzed using multiplex isobaric labeling. Spectral clustering was used to match MS/MS spectra. The top biomarker candidate cluster (215% higher in AD compared to controls, area under ROC curve = 0.96) was identified as a fragment of pleiotrophin located near the protein's C-terminus. Analysis of another cohort (n = 60 over four clinical groups) verified that the biomarker was increased in AD patients while no change in controls, Parkinson's disease or progressive supranuclear palsy was observed. The identification of the novel biomarker pleiotrophin 151-166 demonstrates that our quantification-driven proteomic approach is a promising method for biomarker discovery, which may be universally applicable in clinical proteomics.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?